Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib

First Posted Date: 2005-09-16

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT00182637

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-08-30

Last Posted Date: 2013-05-30

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT00138164

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2005-06-03

Last Posted Date: 2013-05-30

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00112983

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Phase 2

Conditions: Leukemia

First Posted Date: 2005-06-03

Last Posted Date: 2011-06-07

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00112775

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Fatigue

Interventions: Biological: infliximab
Other: Clinical Assessment
Other: Self-report questionnaires
Other: Immune Assessment

First Posted Date: 2005-06-03

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00112749

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2005-04-06

Last Posted Date: 2013-11-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 37

Registration Number: NCT00107159

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: therapeutic autologous dendritic cells

First Posted Date: 2005-04-06

Last Posted Date: 2020-08-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00107185

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: celecoxib

First Posted Date: 2005-03-04

Last Posted Date: 2015-10-02

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00104767

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-01-10

Last Posted Date: 2013-07-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00100997

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2008-01-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT00098917

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy